Global Diabetic Nephropathy

Diabetic Nephropathy Comprehensive Study by Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Treatment (Medication, Kidney Dialysis, Kidney Transplant), Stages (Microalbuminuria (UAE >20 μg/min and ≤199 μg/min), Macroalbuminuria (UAE ≥200 μg/min)), Tests (Blood Test, Urine Test, Imaging Test, Renal Function Test, Kidney Biopsy) Players and Region - Global Market Outlook to 2030

Diabetic Nephropathy Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Diabetic Nephropathy Market Overview:
Diabetic nephropathy which is the end of kidney disease due to the result of diabetes, the global diabetic nephropathy market is driven by high blood pressure and glucose level. Having high blood glucose levels due to diabetes can damage the part of the kidneys that filter the blood. For some people, it can progress to chronic disease and its failure, it is common in women every one out of 4 women and every one out of 5 men are diagnosed with type 2 diabetic nephropathy. It is even more common in type 1 diabetes. As per latest study released by AMA Research, the Global Diabetic Nephropathy market is expected to see growth rate of 5.9%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Automation in Diabetic Nephropathy Devices for Treatment and Most Women are Being Diagnosed with Diabetic Nephropathy

Market Growth Drivers:
Growing Number of Patients with Diabetes Around the World and Prevalence of High Blood Pressure and Cardiovascular Disease

Challenges:
Stiff Competition in Diabetic Nephropathy Market

Restraints:
Stringent Regulatory Guidelines on Diabetic Nephropathy Drugs and Devices

Opportunities:
Awareness about Kidney Related Problems, Surging Investment in Research and Development in Drug Discovery and Technological Advancements in Diabetic Nephropathy Devices and Treatments

Competitive Landscape:
The key players are targeting the innovations of the Solutions with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions to maintain their presence in the market.
Some of the key players profiled in the report are Novartis International AG (Switzerland), Merck & Co., Inc. (United States), Pfizer Inc. (United States), Abbott Laboratories (United States), Vifor Pharma Group (Switzerland), Bayer AG (Germany), Sanofi S.A. (France), Mitsubishi Tanabe Pharma Corporation (Japan), Mesoblast Ltd (Australia), Eli Lilly and Company (United States), AbbVie Inc. (United States) and Reata Pharmaceuticals, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Diabetic Nephropathy market by 2030. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Diabetic Nephropathy market. Considering Market by Stages, the sub-segment i.e. Microalbuminuria (UAE >20 μg/min and ≤199 μg/min) will boost the Diabetic Nephropathy market. Considering Market by Tests, the sub-segment i.e. Blood Test will boost the Diabetic Nephropathy market.

Latest Market Insights:
On December 15, 2023, Kiromic, a developer of AI-powered kidney disease diagnostics, announced its acquisition by Veracyte, a global diagnostics leader. This acquisition strengthens Veracyte's offerings in early-stage kidney disease detection and potentially paves the way for personalized treatment approaches for diabetic nephropathy.

In July 2021, The FDA has approved Bayer's Kerendia (pinerenone) tablets to reduce the risk of hospitalization for kidney failure, renal failure, nonfatal heart attack, cardiovascular death, and heart failure in adults with chronic kidney disease associated with type 2 diabetes.

What Can be Explored with the Diabetic Nephropathy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Diabetic Nephropathy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Diabetic Nephropathy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Diabetic Nephropathy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Diabetic Nephropathy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Diabetic Nephropathy Treatment Providers, Diabetic Nephropathy Diagnostic Device Manufacturers, Research and Development Institutes, Regulatory Bodies, Potential Investors, Hospitals, Industry Associations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Cancer Research Institutes
  • Diagnostic Labs
By Treatment
  • Medication
  • Kidney Dialysis
  • Kidney Transplant

By Stages
  • Microalbuminuria (UAE >20 μg/min and ≤199 μg/min)
  • Macroalbuminuria (UAE ≥200 μg/min)

By Tests
  • Blood Test
  • Urine Test
  • Imaging Test
  • Renal Function Test
  • Kidney Biopsy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Patients with Diabetes Around the World
      • 3.2.2. Prevalence of High Blood Pressure and Cardiovascular Disease
    • 3.3. Market Challenges
      • 3.3.1. Stiff Competition in Diabetic Nephropathy Market
    • 3.4. Market Trends
      • 3.4.1. Automation in Diabetic Nephropathy Devices for Treatment
      • 3.4.2. Most Women are Being Diagnosed with Diabetic Nephropathy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetic Nephropathy, by Application, Treatment, Stages, Tests and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Diabetic Nephropathy (Value)
      • 5.2.1. Global Diabetic Nephropathy by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Cancer Research Institutes
        • 5.2.1.3. Diagnostic Labs
      • 5.2.2. Global Diabetic Nephropathy by: Treatment (Value)
        • 5.2.2.1. Medication
        • 5.2.2.2. Kidney Dialysis
        • 5.2.2.3. Kidney Transplant
      • 5.2.3. Global Diabetic Nephropathy by: Stages (Value)
        • 5.2.3.1. Microalbuminuria (UAE >20 μg/min and ≤199 μg/min)
        • 5.2.3.2. Macroalbuminuria (UAE ≥200 μg/min)
      • 5.2.4. Global Diabetic Nephropathy by: Tests (Value)
        • 5.2.4.1. Blood Test
        • 5.2.4.2. Urine Test
        • 5.2.4.3. Imaging Test
        • 5.2.4.4. Renal Function Test
        • 5.2.4.5. Kidney Biopsy
      • 5.2.5. Global Diabetic Nephropathy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Diabetic Nephropathy (Price)
  • 6. Diabetic Nephropathy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vifor Pharma Group (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mesoblast Ltd (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AbbVie Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Reata Pharmaceuticals, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Diabetic Nephropathy Sale, by Application, Treatment, Stages, Tests and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Diabetic Nephropathy (Value)
      • 7.2.1. Global Diabetic Nephropathy by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Cancer Research Institutes
        • 7.2.1.3. Diagnostic Labs
      • 7.2.2. Global Diabetic Nephropathy by: Treatment (Value)
        • 7.2.2.1. Medication
        • 7.2.2.2. Kidney Dialysis
        • 7.2.2.3. Kidney Transplant
      • 7.2.3. Global Diabetic Nephropathy by: Stages (Value)
        • 7.2.3.1. Microalbuminuria (UAE >20 μg/min and ≤199 μg/min)
        • 7.2.3.2. Macroalbuminuria (UAE ≥200 μg/min)
      • 7.2.4. Global Diabetic Nephropathy by: Tests (Value)
        • 7.2.4.1. Blood Test
        • 7.2.4.2. Urine Test
        • 7.2.4.3. Imaging Test
        • 7.2.4.4. Renal Function Test
        • 7.2.4.5. Kidney Biopsy
      • 7.2.5. Global Diabetic Nephropathy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Diabetic Nephropathy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetic Nephropathy: by Application(USD Million)
  • Table 2. Diabetic Nephropathy Hospitals , by Region USD Million (2018-2023)
  • Table 3. Diabetic Nephropathy Cancer Research Institutes , by Region USD Million (2018-2023)
  • Table 4. Diabetic Nephropathy Diagnostic Labs , by Region USD Million (2018-2023)
  • Table 5. Diabetic Nephropathy: by Treatment(USD Million)
  • Table 6. Diabetic Nephropathy Medication , by Region USD Million (2018-2023)
  • Table 7. Diabetic Nephropathy Kidney Dialysis , by Region USD Million (2018-2023)
  • Table 8. Diabetic Nephropathy Kidney Transplant , by Region USD Million (2018-2023)
  • Table 9. Diabetic Nephropathy: by Stages(USD Million)
  • Table 10. Diabetic Nephropathy Microalbuminuria (UAE >20 μg/min and ≤199 μg/min) , by Region USD Million (2018-2023)
  • Table 11. Diabetic Nephropathy Macroalbuminuria (UAE ≥200 μg/min) , by Region USD Million (2018-2023)
  • Table 12. Diabetic Nephropathy: by Tests(USD Million)
  • Table 13. Diabetic Nephropathy Blood Test , by Region USD Million (2018-2023)
  • Table 14. Diabetic Nephropathy Urine Test , by Region USD Million (2018-2023)
  • Table 15. Diabetic Nephropathy Imaging Test , by Region USD Million (2018-2023)
  • Table 16. Diabetic Nephropathy Renal Function Test , by Region USD Million (2018-2023)
  • Table 17. Diabetic Nephropathy Kidney Biopsy , by Region USD Million (2018-2023)
  • Table 18. South America Diabetic Nephropathy, by Country USD Million (2018-2023)
  • Table 19. South America Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 20. South America Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 21. South America Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 22. South America Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 23. Brazil Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 24. Brazil Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 25. Brazil Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 26. Brazil Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 27. Argentina Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 28. Argentina Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 29. Argentina Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 30. Argentina Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 31. Rest of South America Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 33. Rest of South America Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 34. Rest of South America Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 35. Asia Pacific Diabetic Nephropathy, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 38. Asia Pacific Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 39. Asia Pacific Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 40. China Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 41. China Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 42. China Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 43. China Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 44. Japan Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 45. Japan Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 46. Japan Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 47. Japan Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 48. India Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 49. India Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 50. India Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 51. India Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 52. South Korea Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 53. South Korea Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 54. South Korea Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 55. South Korea Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 56. Taiwan Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 57. Taiwan Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 58. Taiwan Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 59. Taiwan Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 60. Australia Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 61. Australia Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 62. Australia Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 63. Australia Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 68. Europe Diabetic Nephropathy, by Country USD Million (2018-2023)
  • Table 69. Europe Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 70. Europe Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 71. Europe Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 72. Europe Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 73. Germany Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 74. Germany Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 75. Germany Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 76. Germany Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 77. France Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 78. France Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 79. France Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 80. France Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 81. Italy Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 82. Italy Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 83. Italy Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 84. Italy Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 85. United Kingdom Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 87. United Kingdom Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 88. United Kingdom Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 89. Netherlands Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 90. Netherlands Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 91. Netherlands Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 92. Netherlands Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 93. Rest of Europe Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 95. Rest of Europe Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 96. Rest of Europe Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 97. MEA Diabetic Nephropathy, by Country USD Million (2018-2023)
  • Table 98. MEA Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 99. MEA Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 100. MEA Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 101. MEA Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 102. Middle East Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 103. Middle East Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 104. Middle East Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 105. Middle East Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 106. Africa Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 107. Africa Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 108. Africa Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 109. Africa Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 110. North America Diabetic Nephropathy, by Country USD Million (2018-2023)
  • Table 111. North America Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 112. North America Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 113. North America Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 114. North America Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 115. United States Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 116. United States Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 117. United States Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 118. United States Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 119. Canada Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 120. Canada Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 121. Canada Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 122. Canada Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 123. Mexico Diabetic Nephropathy, by Application USD Million (2018-2023)
  • Table 124. Mexico Diabetic Nephropathy, by Treatment USD Million (2018-2023)
  • Table 125. Mexico Diabetic Nephropathy, by Stages USD Million (2018-2023)
  • Table 126. Mexico Diabetic Nephropathy, by Tests USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Diabetic Nephropathy: by Application(USD Million)
  • Table 140. Diabetic Nephropathy Hospitals , by Region USD Million (2025-2030)
  • Table 141. Diabetic Nephropathy Cancer Research Institutes , by Region USD Million (2025-2030)
  • Table 142. Diabetic Nephropathy Diagnostic Labs , by Region USD Million (2025-2030)
  • Table 143. Diabetic Nephropathy: by Treatment(USD Million)
  • Table 144. Diabetic Nephropathy Medication , by Region USD Million (2025-2030)
  • Table 145. Diabetic Nephropathy Kidney Dialysis , by Region USD Million (2025-2030)
  • Table 146. Diabetic Nephropathy Kidney Transplant , by Region USD Million (2025-2030)
  • Table 147. Diabetic Nephropathy: by Stages(USD Million)
  • Table 148. Diabetic Nephropathy Microalbuminuria (UAE >20 μg/min and ≤199 μg/min) , by Region USD Million (2025-2030)
  • Table 149. Diabetic Nephropathy Macroalbuminuria (UAE ≥200 μg/min) , by Region USD Million (2025-2030)
  • Table 150. Diabetic Nephropathy: by Tests(USD Million)
  • Table 151. Diabetic Nephropathy Blood Test , by Region USD Million (2025-2030)
  • Table 152. Diabetic Nephropathy Urine Test , by Region USD Million (2025-2030)
  • Table 153. Diabetic Nephropathy Imaging Test , by Region USD Million (2025-2030)
  • Table 154. Diabetic Nephropathy Renal Function Test , by Region USD Million (2025-2030)
  • Table 155. Diabetic Nephropathy Kidney Biopsy , by Region USD Million (2025-2030)
  • Table 156. South America Diabetic Nephropathy, by Country USD Million (2025-2030)
  • Table 157. South America Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 158. South America Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 159. South America Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 160. South America Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 161. Brazil Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 162. Brazil Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 163. Brazil Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 164. Brazil Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 165. Argentina Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 166. Argentina Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 167. Argentina Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 168. Argentina Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 169. Rest of South America Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 170. Rest of South America Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 171. Rest of South America Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 172. Rest of South America Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 173. Asia Pacific Diabetic Nephropathy, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 175. Asia Pacific Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 176. Asia Pacific Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 177. Asia Pacific Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 178. China Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 179. China Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 180. China Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 181. China Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 182. Japan Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 183. Japan Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 184. Japan Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 185. Japan Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 186. India Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 187. India Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 188. India Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 189. India Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 190. South Korea Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 191. South Korea Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 192. South Korea Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 193. South Korea Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 194. Taiwan Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 195. Taiwan Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 196. Taiwan Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 197. Taiwan Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 198. Australia Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 199. Australia Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 200. Australia Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 201. Australia Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 206. Europe Diabetic Nephropathy, by Country USD Million (2025-2030)
  • Table 207. Europe Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 208. Europe Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 209. Europe Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 210. Europe Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 211. Germany Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 212. Germany Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 213. Germany Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 214. Germany Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 215. France Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 216. France Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 217. France Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 218. France Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 219. Italy Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 220. Italy Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 221. Italy Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 222. Italy Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 223. United Kingdom Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 224. United Kingdom Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 225. United Kingdom Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 226. United Kingdom Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 227. Netherlands Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 228. Netherlands Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 229. Netherlands Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 230. Netherlands Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 231. Rest of Europe Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 232. Rest of Europe Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 233. Rest of Europe Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 234. Rest of Europe Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 235. MEA Diabetic Nephropathy, by Country USD Million (2025-2030)
  • Table 236. MEA Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 237. MEA Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 238. MEA Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 239. MEA Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 240. Middle East Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 241. Middle East Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 242. Middle East Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 243. Middle East Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 244. Africa Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 245. Africa Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 246. Africa Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 247. Africa Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 248. North America Diabetic Nephropathy, by Country USD Million (2025-2030)
  • Table 249. North America Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 250. North America Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 251. North America Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 252. North America Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 253. United States Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 254. United States Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 255. United States Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 256. United States Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 257. Canada Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 258. Canada Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 259. Canada Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 260. Canada Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 261. Mexico Diabetic Nephropathy, by Application USD Million (2025-2030)
  • Table 262. Mexico Diabetic Nephropathy, by Treatment USD Million (2025-2030)
  • Table 263. Mexico Diabetic Nephropathy, by Stages USD Million (2025-2030)
  • Table 264. Mexico Diabetic Nephropathy, by Tests USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetic Nephropathy: by Application USD Million (2018-2023)
  • Figure 5. Global Diabetic Nephropathy: by Treatment USD Million (2018-2023)
  • Figure 6. Global Diabetic Nephropathy: by Stages USD Million (2018-2023)
  • Figure 7. Global Diabetic Nephropathy: by Tests USD Million (2018-2023)
  • Figure 8. South America Diabetic Nephropathy Share (%), by Country
  • Figure 9. Asia Pacific Diabetic Nephropathy Share (%), by Country
  • Figure 10. Europe Diabetic Nephropathy Share (%), by Country
  • Figure 11. MEA Diabetic Nephropathy Share (%), by Country
  • Figure 12. North America Diabetic Nephropathy Share (%), by Country
  • Figure 13. Global Diabetic Nephropathy share by Players 2023 (%)
  • Figure 14. Global Diabetic Nephropathy share by Players (Top 3) 2023(%)
  • Figure 15. Global Diabetic Nephropathy share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 25. Vifor Pharma Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Vifor Pharma Group (Switzerland) Revenue: by Geography 2023
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 29. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 31. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2023
  • Figure 33. Mesoblast Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 34. Mesoblast Ltd (Australia) Revenue: by Geography 2023
  • Figure 35. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 37. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Reata Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Reata Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Global Diabetic Nephropathy: by Application USD Million (2025-2030)
  • Figure 42. Global Diabetic Nephropathy: by Treatment USD Million (2025-2030)
  • Figure 43. Global Diabetic Nephropathy: by Stages USD Million (2025-2030)
  • Figure 44. Global Diabetic Nephropathy: by Tests USD Million (2025-2030)
  • Figure 45. South America Diabetic Nephropathy Share (%), by Country
  • Figure 46. Asia Pacific Diabetic Nephropathy Share (%), by Country
  • Figure 47. Europe Diabetic Nephropathy Share (%), by Country
  • Figure 48. MEA Diabetic Nephropathy Share (%), by Country
  • Figure 49. North America Diabetic Nephropathy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Pfizer Inc. (United States)
  • Abbott Laboratories (United States)
  • Vifor Pharma Group (Switzerland)
  • Bayer AG (Germany)
  • Sanofi S.A. (France)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Mesoblast Ltd (Australia)
  • Eli Lilly and Company (United States)
  • AbbVie Inc. (United States)
  • Reata Pharmaceuticals, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 172 Pages 70 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diabetic Nephropathy Quantitative research analysis
Global Diabetic Nephropathy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Diabetic Nephropathy market are Novartis International AG (Switzerland), Merck & Co., Inc. (United States), Pfizer Inc. (United States), Abbott Laboratories (United States), Vifor Pharma Group (Switzerland), Bayer AG (Germany), Sanofi S.A. (France), Mitsubishi Tanabe Pharma Corporation (Japan), Mesoblast Ltd (Australia), Eli Lilly and Company (United States), AbbVie Inc. (United States) and Reata Pharmaceuticals, Inc. (United States), to name a few.
"Automation in Diabetic Nephropathy Devices for Treatment " is seen as one of major influencing trends for Diabetic Nephropathy Market during projected period 2023-2030.

Know More About Global Diabetic Nephropathy Report?

Have a Query? Click Here

Other Related Reports

Negative Pressure Wound Therapy Comprehensive Study by Type (Standalone NPWT Devices, Single use Disposable NPWT Devices, Portable NPWT Devices, NPWT Accessories (Canister)), Application (Hospital, C...
$ 3350
Chitosan Gel Comprehensive Study by Type (Industrial Grade, Pharmaceutical Grade, Others), Application (Surgical, Gynecological Diseases, Hemorrhoid Disease, Others), Distribution Channel (Hospital P...
$ 3450
Rosacea Treatment Comprehensive Study by Type (Erythematotelangiectatic Rosacea, Papulopustular Rosacea, Ocular Rosacea, Phymatous Rosacea), Drugs (Rhofade, Mirvaso, Oracea, Others), Route of Adminis...
$ 3750
Hadron Therapy Comprehensive Study by Type (Electron Beam, Neutron Beam, Alpha Particle Beam, Proton Beam, Carbon Ion Beam, Beta Particle Beam), Application (Treatment Applications, Research Applicat...
$ 3750
Adenomyosis Treatment Comprehensive Study by Type (Focal, Adenomyoma, Diffuse, Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Treatment (Anti-inflammatory Drugs (ibup...
$ 3750
Aneurysmal Subarachnoid Hemorrhage Comprehensive Study by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography, Transcranial Dop...
$ 3650